Selected article for: "immune response trigger and spike protein"

Author: Diotallevi, F.; Campanati, A.; Radi, G.; Martina, E.; Rizzetto, G.; Barbadoro, P.; D'Errico, M.M.; Offidani, A.
Title: Vaccination against SARS‐CoV‐2 and psoriasis: the three things every dermatologist should know
  • Cord-id: hr13taxx
  • Document date: 2021_4_17
  • ID: hr13taxx
    Snippet: Currently there are two vaccines already authorized from FDA and EMA for Emergency Use (1). They are the BNT162b2 and the mRNA-1273, respectively produced by Pfizer/BioNTech® and Moderna® (Tab.1). Both vaccines consist of nucleic acid, mRNA able to induce our human cells to use protein factories to make the antigen (viral spike protein) that will trigger an immune response.
    Document: Currently there are two vaccines already authorized from FDA and EMA for Emergency Use (1). They are the BNT162b2 and the mRNA-1273, respectively produced by Pfizer/BioNTech® and Moderna® (Tab.1). Both vaccines consist of nucleic acid, mRNA able to induce our human cells to use protein factories to make the antigen (viral spike protein) that will trigger an immune response.

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1
    Co phrase search for related documents, hyperlinks ordered by date